Business Context and Reporting Period
This Form 8-K Current Report was filed by CG Oncology, Inc. on April 13, 2026. The filing discloses the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Jim DeTore as Chief Financial Officer, effective April 13, 2026. Mr. DeTore transitions from his role as Interim Principal Financial and Accounting Officer, a position he held since November 2025.
Management Commentary, Risks, and Unusual Items
Compensation and Employment Terms
- Base Salary: $520,000 annually.
- Target Bonus: 45% of annual base salary.
- Equity Awards:
- Initial Stock Option with a target value of $4 million, vesting over four years (25% after 12 months, remainder monthly).
- Performance Stock Unit (PSU) Award with a target value of $1 million.
- PSU Vesting Conditions:
- 30% vests upon the first U.S. commercial sale of the Company's first approved product.
- 70% vests upon achievement of positive operating cash flow for two consecutive completed fiscal quarters following commercial launch.
Severance Provisions
- Termination Without Cause (Outside Change in Control): One year of base salary, prorated target bonus, 12 months of COBRA, and 12 months of accelerated equity vesting.
- Termination Without Cause/Good Reason (Within Change in Control): 1.5 times base salary, full target bonus, 18 months of COBRA, and full acceleration of unvested equity (performance-based awards remain subject to goals).
Investor Verification Checklist
- Verify the grant date (April 15, 2026) and exercise price for the $4 million stock option award.
- Confirm the specific performance metrics and certification process for the $1 million PSU award tied to commercial launch and positive operating cash flow.
- Review the full Employment Agreement (Exhibit 10.1) for detailed definitions of "Good Reason" and "Change in Control."
- Assess the impact of the new CFO's compensation structure on future cash burn and dilution.